GlycoNex (4168) - Total Liabilities
Based on the latest financial reports, GlycoNex (4168) has total liabilities worth NT$542.22 Million TWD (≈ $17.08 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GlycoNex asset resilience ratio to evaluate the company's liquid asset resilience ratio.
GlycoNex - Total Liabilities Trend (2017–2024)
This chart illustrates how GlycoNex's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GlycoNex total assets.
GlycoNex Competitors by Total Liabilities
The table below lists competitors of GlycoNex ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lokesh Machines Limited
NSE:LOKESHMACH
|
India | Rs2.33 Billion |
|
mPLUS Corp
KQ:259630
|
Korea | ₩122.63 Billion |
|
Lifetime Brands Inc
NASDAQ:LCUT
|
USA | $396.48 Million |
|
Adrad Holdings Ltd
AU:AHL
|
Australia | AU$64.07 Million |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
India | Rs3.23 Billion |
|
SMJ International Holdings Inc.
NYSE MKT:SMJF
|
USA | $10.23 Million |
|
Alithya Group Inc
NASDAQ:ALYAF
|
USA | $232.21 Million |
|
Hotron Precision Electronic Industrial Co Ltd
TW:3092
|
Taiwan | NT$3.62 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down GlycoNex's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GlycoNex balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlycoNex's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlycoNex (2017–2024)
The table below shows the annual total liabilities of GlycoNex from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$270.01 Million ≈ $8.51 Million |
-2.31% |
| 2023-12-31 | NT$276.40 Million ≈ $8.71 Million |
+1.87% |
| 2022-12-31 | NT$271.34 Million ≈ $8.55 Million |
+652.25% |
| 2021-12-31 | NT$36.07 Million ≈ $1.14 Million |
+4.65% |
| 2020-12-31 | NT$34.47 Million ≈ $1.09 Million |
+9.91% |
| 2019-12-31 | NT$31.36 Million ≈ $987.98K |
+6.84% |
| 2018-12-31 | NT$29.35 Million ≈ $924.69K |
+16.53% |
| 2017-12-31 | NT$25.19 Million ≈ $793.53K |
-- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more